Mizuho Securities Thinks Akebia Therapeutics’ Stock is Going to Recover
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Akebia Therapeutics (NASDAQ: AKBA), with a price target of $24. The company’s shares closed yesterday at $9.51, close to its 52-week low of $8.93.
According to TipRanks.com, Yang is a 5-star analyst with an average return of 20.0% and a 50.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
Akebia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $24.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20.25 and a one-year low of $8.93. Currently, Akebia Therapeutics has an average volume of 484.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akebia Therapeutics, Inc. is a biopharmaceutical company which engages in the development of novel proprietary therapeutics based on hypoxia-inducible factor and biology. It also includes the development and commercialization of drugs for the treatment of renal and metabolic disorders.